NSEPendency of Litigation(s)/dispute(s) or the outcome impacting the Company29 Sept 2026 · 29 Sept 2026, 05:57 pm
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited · PANACEABIO
✦ AI Summary▼ NegativeLitigation
Panacea Biotec Limited has received two Demand Orders from the Office of the Assistant Commissioner of Income Tax, Delhi, imposing a penalty of ~₹4.32 Crore on account of alleged misreporting/under reporting of income for Assessment Years 2022-23 and 2023-24.
Analysis Scores
Earnings Impact2/10
Growth Catalyst1/10
Governance Concern6/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact5/10
Market Sentiment2/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Attachments (1)
📄pdf
Download →
PANACEABIO_29092026175638_IntimationofDemandOrder29092026signed.pdf
View document text
September 29, 2026
The Manager, Listing Department BSE Limited
The National Stock Exchange of India Ltd. Corporate Relationship Department,
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers,
Bandra (E), Mumbai - 400051 Dalal Street, Mumbai - 400001
NSE Symbol: PANACEABIO BSE Scrip Code: 531349
Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (“SEBI LODR Regulations”)
Dear Sir / Madam,
Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we would like to inform you
that the Company has received on September 29, 2026, two (2) Demand Orders dated September 28,
2026, from the Office of the Assistant Commissioner of Income Tax, Delhi under Section 156 of the
Income Tax Act, 1961 (“Act”) imposing penalty on account of alleged misreporting / under reporting of
income, resulting into demand aggregating to ~₹4.32 Crore as per details given in the enclosed Annexure.
The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI
Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry
Standards on Regulation 30 of SEBI LODR Regulations is annexed herewith as Annexure A.
This is for your kind information and record please.
Thanking you,
Sincerely yours,
For Panacea Biotec Limited
Ankit Jain
General Manager – Legal & Company Secretary
Encl. As above
Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)
Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab
Correspondence/Corporate office : B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com
Annexure A
Details required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular
No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on
Regulation 30 of SEBI LODR Regulations
# Particulars Details
1 Name of the Listed Entity Panacea Biotec Limited
2 Type of communication received The Company has received two Demand Orders from Office of the
Assistant Commissioner of Income Tax, Delhi under the Income
Tax Act, 1961 (“Act”)
3 Date of receipt of communication 29.09.2026
4 Authority from whom communication Office of the Assistant Commissioner of Income Tax, Delhi
received
5 Brief summary of the material Two Demand Orders u/s 156 of the Act raising aggregate demand
contents of the communication of ~₹4.32 Crore towards penalty on account of alleged misreporting
received, including reasons for receipt / under reporting of income.
of the communication
6 Period for which communication Assessment Years 2022-23 and 2023-24.
would be applicable, if stated
7 Expected financial implications on the Based on the Company’s assessment, the aforesaid demand is not
listed company, if any maintainable, and the Company is taking all necessary steps
including filing an Appeal with appellate authority against the said
demand. The Company does not envisage any significant impact
on financial, operation or other activities of the Company.
8 Details of any aberrations/non- Not Applicable
compliances identified by the
authority in the communication
9 Details of any penalty or restriction or The department has alleged misreporting / under reporting of
sanction imposed pursuant to the income in the assessment orders passed earlier and has imposed
communication penalty of ~₹4.32 Crore under Section 270A of the Act.
10 Action(s) taken by listed company Not Applicable
with respect to the communication
11 Any other relevant information Not Applicable
Thanking you,
Sincerely yours,
For Panacea Biotec Limited
Ankit Jain
General Manager – Legal & Company Secretary
Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)
Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab
Correspondence/Corporate office : B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com